Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Opinion & Analysis (NYSE:MRK)

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

Streetwise Reports December 10, 2019

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

Streetwise Reports October 4, 2019

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017

Why the election is not as relevant to drug stocks as you might believe

The Life Sciences Report November 4, 2016

Circling the globe for uncommon biotech opportunities

The Life Sciences Report February 18, 2016

Eight ways to leverage the small-cap biotech bull market: Ajay Tandon and Jay Albany of SeeThruEquity

Gail Dutton October 30, 2015

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

Gail Dutton October 1, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Play the gap to profit from Australia's undervalued biotech gems: John Hester of Bell Potter Securities

George S. Mack July 22, 2015

Opportunities in cancer immunotherapy throttle up: George Zavoico of JonesTrading

George S. Mack June 25, 2015

U.S. Tech, Dollar & Health Care ETFs To Watch This Week

Benzinga.com  April 26, 2015

Sector ETFs And Earnings

Benzinga.com  April 7, 2015

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Drug ETFs Attractive Buys On Pullback

Benzinga.com  October 22, 2014

Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

Benzinga.com  August 27, 2014

Healthcare ETFs Leading the Pack This Q2 Earnings - ETF News And Commentary

Benzinga.com  August 7, 2014

Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary

Benzinga.com  July 30, 2014

Pharmaceutical ETFs Are Health Care Sector Standouts

Benzinga.com  July 29, 2014

ETF Outlook For Tuesday, June 10, 2014 (IAT, FXE, PBE, HYHG, IDIX, MRK)

Benzinga.com  June 10, 2014